Targeting SLC7A11/xCT improves radiofrequency ablation efficacy of HCC by dendritic cells mediated anti-tumor immune response

Yuzhao Jin; Songhua Cai; Yang Zhou; Dandan Guo; Yuzhen Zeng; Wangting Xu; Yiting Sun; Yueli Shi; Zhiyong Xu; Zaoqu Liu; Peng Luo; Zhao Huang; Bufu Tang

doi:10.1002/imt2.248

Targeting SLC7A11/xCT improves radiofrequency ablation efficacy of HCC by dendritic cells mediated anti-tumor immune response

Imeta. 2024 Nov 20;3(6):e248. doi: 10.1002/imt2.248. eCollection 2024 Dec.

Authors

Yuzhao Jin¹, Songhua Cai², Yang Zhou³, Dandan Guo⁴, Yuzhen Zeng⁵, Wangting Xu⁶, Yiting Sun⁷, Yueli Shi⁸, Zhiyong Xu⁸, Zaoqu Liu⁹, Peng Luo¹⁰, Zhao Huang^{11

12}, Bufu Tang^{4

5}

Affiliations

¹ Postgraduate Training Base Wenzhou Medical University Wenzhou China.
² Department of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen China.
³ Department of Gynecologic Oncology Zhongshan Hospital, Fudan University Shanghai China.
⁴ Department of Oncology First Affiliated Hospital, Dalian Medical University Dalian China.
⁵ Department of Radiation Oncology Zhongshan Hospital Affiliated to Fudan University Shanghai China.
⁶ Department of Respiratory Medicine Sir Run Run Shaw Hospital, Zhejiang University Hangzhou China.
⁷ Department of Clinical Medicine China Medical University Shenyang China.
⁸ Department of Respiratory and Critical Medicine Center for Oncology Medicine, The Fourth Affiliated Hospital of School of Medicine, International Institutes of Medicine, Zhejiang University Yiwu City China.
⁹ Institute of Basic Medical Sciences Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
¹⁰ Department of Oncology Zhujiang Hospital, Southern Medical University Guangzhou Guangdong China.
¹¹ Hepatic Surgery Center Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China.
¹² Hubei Key Laboratory of Hepato-Pancreatic-Biliary Diseases Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China.

Abstract

After RFA treatment in patients with liver cancer, the expression of SLC7A11/xCT and the proportion of DCs in the TME were significantly increased. SLC7A11/xCT is a poor prognostic marker for liver cancer and is mainly expressed in DCs in the TME. Targeting xCT in DCs combined with RFA significantly enhances anti-tumor immunity, suppressing tumor growth and offering a promising strategy for improved therapeutic outcomes in liver cancer.